

The information in this announcement is NOT for publication OR distribution in or into the United States of America, Australia, Canada or any jurisdiction in which such distribution or publication could be unlawful

PRESS RELEASE

Elanix Biotechnologies AG Announces Subscription Period and Subsequent Private Placement to Commence on November 23, 2017

Berlin, 22 November 2017 – [Elanix Biotechnologies AG](#) ("Elanix"; "Company"), a developer of tissue regeneration products and specialty cosmetics in the field of dermatology and gynecology, announced today that the subscription period for its planned capital increase will begin as announced on 23 November 2017. During the subscription period, which lasts until 7 December 2017, shareholders, by way of their depository bank, may exercise their subscription rights (ISIN DE000A2GSU83) and can subscribe to new shares of the Company at a ratio of 4:1 (four existing shares allow a subscription of one new share) at a price of EUR 3.75 per new share. In keeping with the resolution passed at the Annual General Meeting of 24 August 2017, a discount of 10% is granted on the average share price (EUR 4.19) of the last five days of trading before fixing the final issue price.

In addition, shareholders can register for a so-called "oversubscription" through their depository bank but will not automatically be guaranteed an allotment of shares. Any shares not purchased within the pre-emptive rights offer will be offered to selected investors in the form of a private placement. The price for the private placement is yet to be set by the Company and will be above the rights offering price level. Up to 1,699,800 new shares can be offered by the Company as part of the capital increase.

The pre-emptive rights offer and prospectus are available on the company website at <https://elanixbiotechnologies.com/> under Capital Increase in the Investor Relations section.

Tomas Svoboda, CEO of Elanix Biotechnologies AG commented: "We have made excellent progress in the first ten months of 2017. In addition to expanding our team in sales and

product management, Elanix has received regulatory approval and initiated the EU market launch of the CFPC (cell-free protein complex) cream GynRepair[®], as well as developed a user app and an online shop. The market launch of the product SKINrepair[®], which can be applied to wounds on the entire body, is being prepared for launch in various EU countries in the first half of 2018. We intend to use the funds raised from the capital increase to finance the next stages of our company development and our commercialisation strategy, as well as to stimulate sales in Europe. We have already taken a vital step in this direction by establishing our offices in Wiesbaden, creating a German subsidiary. "

Press Contacts:

Elanix Biotechnologies

Tomas Svoboda, CEO

Tel: +41 (0)22 363 66 40

investor.relations@elanix-bt.com

Halsin Partners

Mike Sinclair

Tel: +44 (0)20 7318 2955

msinclair@halsin.com

Forward-looking statements:

This publication may contain certain forward-looking statements regarding the Company and its business activities. Such statements may involve certain risks, uncertainties and other factors which can lead to the results, financial situation, performance and success of the Company differing significantly in reality from what is expressed or implied by such statements. The reader should therefore not place undue trust in these statements, especially in connection with contracts and investment decisions. The Company does not accept any obligation to update such forward-looking statements.

Disclaimer

This communication may not be published or distributed in the United States of America (including its territories and possessions), Canada, Japan or Australia or in any other countries in which such publication and distribution might be illegal. The distribution of this publication may be subject to legal restrictions in some countries; anyone in possession of this document or of the information referred to in it should obtain information regarding such restrictions and adhere to them. Non-adherence to such restrictions may constitute a breach of capital market law in such countries.

This communication is neither an offer nor an invitation to subscribe for or purchase shares of Elanix Biotechnologies AG in the United States of America, Germany or any other country. Neither does this

communication constitute a prospectus under Directive 2003/71/EC of the European Parliament and Council dated 4 November 2003 as amended (the "Prospectus Directive"). The public offering in Germany is carried out solely by means of and based on the share prospectus approved by the Federal Supervisory Financial Authority (BaFin). This share prospectus is published on the Elanix Biotechnologies AG website (<https://elanixbiotechnologies.com/Investor> Relations). Any investment decision relating to Elanix Biotechnologies AG subscription rights or shares should be made based on the prospectus.

Neither this publication nor its content may be used as a basis for an offer in any country. The shares referred to above may be neither sold nor offered in the United States of America insofar as no registration has been undertaken or insofar as no exception from the registration requirement applies under the United States Securities Act of 1933 as last amended ("Securities Act"). Elanix Biotechnologies AG shares are not and will not be registered according to the Securities Act.

This communication does not constitute a recommendation relating to the placement of the shares described in this notice. Investors should consult a professional advisor in determining the suitability of the offer to the individual concerned.

In the United Kingdom, this publication is only intended for (i) professional investors who fall under Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (hereinafter referred to as "Order") or (ii) persons who fall under Article 49(2) (a) to (d) of the Order (high net worth companies, private companies, etc.) (such persons are referred to collectively hereinafter as "Relevant Persons"). Persons other than Relevant Persons may not refer to this publication or rely on it. Any investment or potential investment referred to in this publication is solely open to Relevant Persons and is only entered into by Relevant Persons.

In member states of the European Economic Area which have implemented the Prospectus Directive (the "Relevant Member States"), this publication and any subsequent offer is aimed solely at "qualified investors" as defined by the Prospectus Directive. For these purposes, "Prospectus Directive" refers to Directive 2003/71/EC (including all amendments, in particular Directive 2010/73/EU) and includes all relevant implementation measures in the Relevant Member States.

No measures have been taken that would allow the shares to be offered or purchased or this publication to be distributed in countries in which this is not permitted. Anyone coming into possession of this publication must obtain information regarding any restrictions themselves and observe these accordingly.